Published in Gastroenterology on May 05, 2007
CE-U and MRE to Predict the Efficacy of Anti-TNF Therapy in Crohn's Disease (CREOLE) | NCT01183403
TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol (2007) 2.17
Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol (2011) 1.45
Intraperitoneal but not intravenous cryopreserved mesenchymal stromal cells home to the inflamed colon and ameliorate experimental colitis. PLoS One (2012) 1.28
Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica (2009) 1.23
Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. Proc Natl Acad Sci U S A (2011) 1.11
Oxymatrine prevents NF-κB nuclear translocation and ameliorates acute intestinal inflammation. Sci Rep (2013) 1.02
Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells. Gastroenterology (2011) 0.96
Effect of infliximab on small bowel stenoses in patients with Crohn's disease. World J Gastroenterol (2008) 0.94
Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease. Clin Exp Immunol (2010) 0.91
Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease. Clin Exp Immunol (2013) 0.91
Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review. Fibrogenesis Tissue Repair (2014) 0.89
Sacral nerve stimulation enhances early intestinal mucosal repair following mucosal injury in a pig model. J Physiol (2016) 0.89
Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values. Int J Colorectal Dis (2009) 0.89
Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats. J Biol Chem (2009) 0.88
Tumor necrosis factor α stimulates endothelin-1 synthesis in rat hepatic stellate cells in hepatic wound healing through a novel IKK/JNK pathway. Exp Cell Res (2011) 0.87
Adalimumab for the treatment of Crohn's disease. Biologics (2008) 0.86
Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J Control Release (2014) 0.83
The role of interleukin 17 in Crohn's disease-associated intestinal fibrosis. Fibrogenesis Tissue Repair (2013) 0.83
Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update. Biomed Res Int (2013) 0.82
Role of MutS homolog 2 (MSH2) in intestinal myofibroblast proliferation during Crohn's disease stricture formation. Am J Physiol Gastrointest Liver Physiol (2008) 0.80
Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease. J Crohns Colitis (2015) 0.79
Tea polyphenols inhibit the activation of NF-κB and the secretion of cytokines and matrix metalloproteinases by macrophages stimulated with Fusobacterium nucleatum. Sci Rep (2016) 0.78
Role of N-acetylcysteine and GSH redox system on total and active MMP-2 in intestinal myofibroblasts of Crohn's disease patients. Int J Colorectal Dis (2012) 0.77
Anti-melanin-concentrating hormone treatment attenuates chronic experimental colitis and fibrosis. Am J Physiol Gastrointest Liver Physiol (2013) 0.77
Inflammatory and Immune Activation in Intestinal Myofibroblasts Is Developmentally Regulated. J Interferon Cytokine Res (2015) 0.77
Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD. United European Gastroenterol J (2016) 0.76
Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol (2016) 0.76
Fibrocytes, inflammation, and fibrosis in Crohn's disease: another piece of the puzzle. Dig Dis Sci (2014) 0.76
Inducible NOS mediates CNP-induced relaxation of intestinal myofibroblasts. Am J Physiol Gastrointest Liver Physiol (2013) 0.75
Phenotypic and functional features of human Th17 cells. J Exp Med (2007) 11.33
Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 7.41
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N Engl J Med (2015) 6.71
Immunity, inflammation, and allergy in the gut. Science (2005) 4.82
Citrobacter rodentium of mice and man. Cell Microbiol (2005) 4.76
Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med (2008) 4.30
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg (2006) 2.97
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology (2005) 2.52
Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis (2005) 2.47
Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest (2005) 2.41
Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med (2011) 2.41
Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology (2008) 2.38
Central role for B lymphocytes and CD4+ T cells in immunity to infection by the attaching and effacing pathogen Citrobacter rodentium. Infect Immun (2003) 2.22
In vivo bioluminescence imaging of the murine pathogen Citrobacter rodentium. Infect Immun (2006) 2.07
Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol (2013) 2.05
The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. Immunity (2012) 1.97
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol (2007) 1.92
Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev (2013) 1.91
Smad7 controls resistance of colitogenic T cells to regulatory T cell-mediated suppression. Gastroenterology (2008) 1.88
Emergence in Italy of Klebsiella pneumoniae sequence type 258 producing KPC-3 Carbapenemase. J Clin Microbiol (2009) 1.86
Regulation of homeostasis and inflammation in the intestine. Gastroenterology (2011) 1.82
Risk of non-Hodgkin lymphoma in celiac disease. JAMA (2002) 1.81
Impaired resistance and enhanced pathology during infection with a noninvasive, attaching-effacing enteric bacterial pathogen, Citrobacter rodentium, in mice lacking IL-12 or IFN-gamma. J Immunol (2002) 1.80
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol (2007) 1.78
IL-23/IL-17 axis in IBD. Inflamm Bowel Dis (2010) 1.71
Randomised controlled trial of health assessments for older Australian veterans and war widows. Med J Aust (2004) 1.62
A milligram of gluten a day keeps the mucosal recovery away: a case report. Nutr Rev (2004) 1.56
Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract. Gastroenterology (2011) 1.55
Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol (2011) 1.55
A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem (2003) 1.54
IL-23-mediated regulation of IL-17 production in Helicobacter pylori-infected gastric mucosa. Eur J Immunol (2008) 1.53
Multivisceral resection for locally advanced gastric cancer: an Italian multicenter observational study. JAMA Surg (2013) 1.53
IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells. Eur J Immunol (2007) 1.49
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med (2009) 1.45
Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol (2005) 1.43
Characterization of IL-17A-producing cells in celiac disease mucosa. J Immunol (2010) 1.40
A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology (2006) 1.38
The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.36
Hyposplenism: a comprehensive review. Part I: basic concepts and causes. Hematology (2007) 1.36
Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.36
Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol (2008) 1.35
The Australian experiment: how primary health care organizations supported the evolution of a primary health care system. J Am Board Fam Med (2012) 1.34
Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol (2008) 1.33
Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol (2004) 1.32
World Gastroenterology Organisation global guidelines on celiac disease. J Clin Gastroenterol (2013) 1.29
Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J Exp Med (2011) 1.27
A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab (2004) 1.25
Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood (2008) 1.25
The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Gastroenterology (2006) 1.24
Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica (2009) 1.23
Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol (2004) 1.22
Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease. J Immunol (2009) 1.22
Bacterial regulation of intestinal immune responses. Gastroenterol Clin North Am (2005) 1.20
Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology (2009) 1.19
Inhibition of NF-κB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE. J Immunol (2010) 1.17
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology (2006) 1.17
A regenerative role for bone marrow following experimental colitis: contribution to neovasculogenesis and myofibroblasts. Gastroenterology (2005) 1.16
The role of psychological stress in inflammatory bowel disease. Neuroimmunomodulation (2007) 1.16
New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.15
The significance of duodenal mucosal atrophy in patients with common variable immunodeficiency: a clinical and histopathologic study. Am J Clin Pathol (2012) 1.14
Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology (2007) 1.14
Post-transcriptional regulation of Smad7 in the gut of patients with inflammatory bowel disease. Gastroenterology (2005) 1.14
Formation of platelet-leukocyte aggregates in inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.12
Altered expression, localization, and phosphorylation of epithelial junctional proteins in celiac disease. Am J Clin Pathol (2006) 1.12
The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway. Proc Natl Acad Sci U S A (2008) 1.12
Nitric oxide in primary ciliary dyskinesia. Eur Respir J (2012) 1.12
Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 1.12
How I treat enteropathy-associated T-cell lymphoma. Blood (2012) 1.11
Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm (2009) 1.10
New treatments for inflammatory bowel disease. World J Gastroenterol (1998) 1.09
Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol (2011) 1.09
Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis (2002) 1.08
Myofibroblast matrix metalloproteinases activate the neutrophil chemoattractant CXCL7 from intestinal epithelial cells. Gastroenterology (2006) 1.08
IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J Immunol (2007) 1.08
The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr Opin Gastroenterol (2012) 1.07
Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol (2007) 1.06
Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. Am J Pathol (2006) 1.06
Alpha-melanocyte-stimulating hormone suppresses antigen-induced lymphocyte proliferation in humans independently of melanocortin 1 receptor gene status. J Immunol (2005) 1.06
Incidence of inflammatory bowel disease is rising and abdominal tuberculosis is falling in Bangladeshis in East London, United Kingdom. Am J Gastroenterol (2004) 1.05
Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication. World J Gastroenterol (2006) 1.04
Emerging immunological targets in inflammatory bowel disease. Curr Opin Pharmacol (2011) 1.04